Nickel-Catalyzed Tandem Reaction to Asymmetric Synthesis of Chiral Phthalides

Jian-Guang Lei; Ran Hong; Shen-Gang Yuan; Guo-Qiang Lin

doi:10.1055/s-2002-31932

LETTER

Nickel-Catalyzed Tandem Reaction to Asymmetric Synthesis of Chiral Phthalides

Jian-Guang Lei, Ran Hong, Shen-Gang Yuan, Guo-Qiang Lin*
Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 354 Fenglin Road, Shanghai, 200032, P. R. China
Fax: +86(21)64166263; e-Mail: lingq@pub.sioc.ac.cn;

Abstract

All articles of this category

Abstract

Nickel-catalyzed tandem (addition-cyclization) reaction was developed to the enantioselective synthesis of optically active phthalides. The choice of bidentate ligand in this nickel-catalyzed reaction was critical to the formation of the phthalides in good yield and high ee value.

Key words

phthalides - nickel-catalyzed - bidentate - enantioselective - tandem reaction

Full Text

References

<A NAME="RY04702ST-1A">1a</A> Grieco PA. Synthesis 1975, 76

<A NAME="RY04702ST-1B">1b</A> Curran D. Chang C.-T. Tetrahedron Lett. 1987, 28: 2477

<A NAME="RY04702ST-1C">1c</A> Demir AS. Gross RS. Dunlap NK. Bashir-Hashemi A. Watt DS. Tetrahedron Lett. 1986, 27: 5567

<A NAME="RY04702ST-1D">1d</A> Tsunoi S. Ryu I. Sonoda N. J. Am. Chem. Soc. 1994, 116: 5473

<A NAME="RY04702ST-1E">1e</A> Matasumoto K. Magashma K. Kamigaucho T. Kawamura Y. Yasuda Y. Ishil K. Uotami N. Sato T. Kahai H. Terui Y. Kipuchi J. Ikewisi Y. Yashida J. Kato T. Itazaki H. J. Antibiot. 1987, 48: 580

<A NAME="RY04702ST-2A">2a</A> Barton DHR. De Vries JX. J. Chem. Soc. 1963, 1916

<A NAME="RY04702ST-2B">2b</A> Zheng GQ. Zhang J. Kenney PM. Lam LKT. ACS Symp. Ser. 1994, 546: 230

<A NAME="RY04702ST-2C">2c</A> Sato H. Yorozu H. Yamaoka S. Biomed. Res. 1993, 14: 385

<A NAME="RY04702ST-2D">2d</A> Yorozu H, and Suzuki T. inventors; JP 03264517. ; Chem. Abstr. 1992, 116, 113352y

<A NAME="RY04702ST-2E">2e</A> Barry RP. Chem. Rev. 1964, 64: 229

<A NAME="RY04702ST-3">3</A> Zheng GQ. Kenny PM. Zhang J. Lam LK. Nutr. Cancer. 1993, 19: 77

<A NAME="RY04702ST-4">4</A> Kobayashi S. Mimura Y. Notaya K. Kimura I. Kimura M. Jpn. J. Pharmacol. 1992, 60: 397

<A NAME="RY04702ST-5">5</A> Yu S. You S. Chen H. Yaoxue Xuebao 1984, 19: 486 ; Chem. Abstr. 1984, 101, 22490c

<A NAME="RY04702ST-6">6</A> Sato H. Yorozu H. Yamaoka S. Biomed. Res. 1993, 14: 385

<A NAME="RY04702ST-7">7</A> Ogawa Y, Hosaka K, Kubota K, and Chin M. inventors; JP 0477480. ; Chem. Abstr. 1992, 117, 69721n.

<A NAME="RY04702ST-8">8</A> Wheeler DD. Young DC. Chem. Abstr 1961, 55: 2577

<A NAME="RY04702ST-9">9</A> Purohit NV. Mukherjee SN. J. Inst. Chemists (India) 1997, 69: 149

<A NAME="RY04702ST-10A">10a</A> Elander M. Leander K. Luning B. Acta Chem. Scand. 1969, 23: 2177

<A NAME="RY04702ST-10B">10b</A> Hung TV. Mooney BA. Prager RH. Tippett JM. Aust. J. Chem. 1981, 34: 383

<A NAME="RY04702ST-11A">11a</A> Chiral aryllithium reagents: Alexakis A. Sedrani R. Normant J.-F. Mangeney P. Tetrahedron: Asymmetry 1990, 1: 283

<A NAME="RY04702ST-11B">11b</A> Also see: Takahashi H. Tsubuki T. Higashiyama K. Chem. Pharm. Bull. 1991, 39: 3136

<A NAME="RY04702ST-11C">11c</A> Dialkyzinc reagents: Soai K. Hori H. Kawahara M. Tetrahedron: Asymmetry 1991, 2: 253

<A NAME="RY04702ST-11D">11d</A> Also see: Watanabe M. Hashimoto N. Araki S. Butsugan Y. J. Org. Chem. 1992, 57: 742

<A NAME="RY04702ST-11E">11e</A> Bioreduction: Kitayama T. Tetrahedron: Asymmetry 1997, 8: 2765

<A NAME="RY04702ST-11F">11f</A> Asymmetric transfer hydrogenation: Kathelyne E. Jean-Luc S. Andre M. Jean-Francois C. Tetrahedron Lett. 2001, 42: 1899

<A NAME="RY04702ST-12A">12a</A> Lin G.-Q. Hong R. J. Org. Chem. 2001, 62: 2877

<A NAME="RY04702ST-12B">12b</A> Hong R. Hoen R. Zhang J. Lin G.-Q. Synlett 2001, 1527

Hong, R.; Lei, J.-Q., unpublished works.

<A NAME="RY04702ST-14">14</A> Matsui S. Uejima A. Suzuki Y. Tanaka K. J. Chem. Soc., Perkin Trans. 1 1993, 701

General procedure: The substrates (0.2 mmol), NiCl₂(PPh₃)₂ (0.04 mmol), (S)-BINAP (0.04 mmol), Zn (0.6 mmol) and 2 mL of toluene were added to an oven-dried 10 mL flask and flushed with argon. The reaction mixture was stirred at 90 °C for desired time. TLC detected the reaction progress. When the reaction was complete, the mixture was quenched with 5 mL of 2% HCl(aq) and diluted by 5 mL of CH₂Cl₂ and stirred for 1 hour at room temperature, then the organic layer was separated and the water layer was exacted with CH₂Cl₂ (3 × 20 mL).The combined organic extracts were washed with NaHCO₃(aq) and brine, dried over anhydrous Na₂SO₄, filtered and evaporated the solvent, the residue was purified on silica gel (EtOAc-petroleum ether = 1:3) by column chromatography.

2a.[α]_D ²⁰ -8.7 (0.61, CHCl₃) for 72%ee; ¹H NMR (300 MHz, CDCl₃) δ 3.60 (s, 3 H), 3.66 (s, 3 H), 3.88 (s, 3 H), 3.92 (s, 3 H), 3.93 (s, 3 H), 3.97 (s, 3 H), 6.16 (s, 1 H), 6.87 (s, PhH, 1 H), 7.27 (s, PhH, 1 H); EIMS (m/z, %): 518 (M⁺ + 2, 6.66), 517 (M⁺ + 1, 25.80), 516 (M⁺, 100), 457 (8.30), 389 (11.32), 321 (16.95), 195 (26.04), 181(21.74); FT-IR(KBr): 2941, 1765, 1613, 1583, 1561, 1479, 1102, 474 cm^-1; Anal. calcd for C₂₀H₂₁O₈I: C, 46.53; H, 4.10. Found: C, 46.53; H, 4.13. HPLC (Chiral cel AD, hexane-iPrOH = 80:20, flow rate = 0.7 mL/min) t_R = 11.44 min(minor), t_R = 12.67 min(major).

3a. [α]_D ²⁰ -26 (0.06, CHCl₃) for 17%ee; ¹H NMR (300 MHz, CDCl₃) δ 3.55 (s, 3 H), 3.82 (s, 6 H), 3.84 (s, 3 H), 3.93 (s, 3 H), 3.96 (s, 3 H), 3.97 (s, 3 H), 6.29(s, 1 H), 6.49 (s, PhH, 2 H), 7.21 (s, PhH, 1 H); EIMS (m/z, %) : 391 (M⁺ + 1, 27.02), 390 (M⁺, 100), 375(14.71), 359 (19.84), 315 (11.76), 331 (18.01), 195 (21.02), 181 (8.71); FT-IR (KBr): 2942, 2840, 1762, 1595, 1508, 1479, 1236, 1128, 1106 cm^-1; Anal. calcd for C₂₀H₂₂O₈: C, 61.53; H, 5.68. Found: C, 61.64; H, 5.82. HPLC (Chiral cel AD, hexane-iPrOH = 70:30, flow rate = 0.7 mL/min) t_R = 11.38 min(minor), t_R = 13.47 min(major).

2b.[α]_D ²⁰ -0.4 (1.85, CHCl₃) for 98%ee; ¹H NMR (300 MHz, CDCl₃) δ 3.65 (s, 3 H), 3.71 (s, 3 H), 3.89 (s, 3 H), 3.90 (s, 3 H), 5.96 (d, J = 0.009 Hz, PhH, 1 H), 6.42 (d, J = 0.01 Hz, PhH, 1 H), 6.66 (d, J = 0.006 Hz, PhH, 1 H), 6.88 (s, 1 H), 6.98 (d, J = 0.006 Hz, PhH, 1 H); EIMS (m/z, %): 457 (M⁺ + 1, 22.80), 456 (M⁺, 100), 329 (27.06), 291 (39.26), 227 (8.12), 193 (18.15), 165 (27.23), 151 (17.28); FT-IR (KBr): 3068, 2963, 2936, 2837, 1753, 1625, 1589, 1569, 1450, 1272, 1036, 492 cm^-1. HPLC (Chiral cel AD, hexane-iPrOH = 95:5, flow rate = 0.8 mL/min) t_R = 35.85 min(minor), t_R = 40.37 min(major).

2c. [α]_D ²⁰ -33 (0.22, CHCl₃) for 81% ee; ¹H NMR (300 MHz, CDCl₃) δ 3.65 (s, 3 H), 3.72 (s, 3 H), 3.90 (s, 3 H), 3.91 (s, 3 H), 5.97 (d, J = 2.71 Hz, PhH, 1 H), 6.48 (d, J = 2.71 Hz, PhH, 1 H), 6.67 (d, J = 1.81 Hz, PhH, 1 H), 6.92 (s, 1 H), 6.99 (d, J = 1.83 Hz, PhH, 1 H); EIMS (m/z, %): 410 (M⁺ + 1, 97.77), 408 (M⁺ - 1, 98.20), 329 (39.36), 245 (47.35), 243 (52.18), 193 (42.89), 165(100), 151 (21.29); FT-IR (KBr): 2972, 2941, 2842, 1765, 1628, 1592, 1504, 1463, 1229, 1207, 607 cm^-1; Anal. calcd for C₁₈H₁₇O₆Br: C, 52.83; H, 4.19. Found: C,52.82; H,4.49. HPLC (Chiral cel OJ, hexane-iPrOH = 90:10, flow rate = 0.7 mL/min) t_R = 15.59 min(major), t_R = 21.32 min(minor).

2d. [α]_D ²⁰ -33 (0.38, CHCl₃) for 43%ee; ¹H NMR (300 MHz, CDCl₃) δ 3.61 (s, 3 H), 3.67 (s, 3 H), 3.89 (s, 3 H), 3.93 (s, 3 H), 3.93 (s, 3 H), 3.96 (s, 3 H), 6.17 (s, 1 H), 6.90 (s, PhH, 1 H), 7.22 (s, PhH, 1 H); EIMS (m/z, %): 471 (M⁺ + 2, 23.49), 470 (M⁺ + 1,100), 469 (M⁺, 83.60), 468 (M⁺ - 1, 99.52), 389 (17.06), 275 (18.06), 273 (19.33), 195 (61.66); FT-IR (KBr): 3030, 2941, 2830, 1761, 1617, 1588, 1567, 1479, 1245, 1201, 587 cm^-1; Anal. calcd for C₂₀H₂₁O₈Br: C, 51.19; H, 4.51.Found: C, 50.99; H, 4.36. HPLC (Chiral cel AD, hexane-iPrOH = 80:20, flow rate = 0.7 mL/min) t_R = 10.46min(minor), t_R = 11.61min(major).

2e. [α]_D ²⁰ -48 (0.07, CHCl₃) for 71%ee; ¹H NMR (300 MHz, CDCl₃) δ 3.53 (s, 3 H), 3.84 (s, 3 H), 3.88(s, 3 H), 3.95 (s, 3 H), 6.58 (d, J = 8.44 Hz, PhH, 1 H), 6.78 (d, J = 8.66 Hz, PhH, 1 H), 6.88 (s, 1 H), 7.13 (d, J = 8.23 Hz, PhH, 1 H), 7.69 (d, J = 8.25 Hz, PhH, 1 H); EIMS (m/z, %): 457 (M⁺ + 1,22.80), 456 (M⁺, 100), 397 (15.16), 329 (23.85), 330 (10.84), 298 (11.27), 291 (19.73), 165 (22.55); FT-IR (KBr): 3051, 2980, 1765, 1580, 1483, 1203, 1116, 539 cm^-1; HPLC (Chiral cel AD, hexane-iPrOH = 70:30, flow rate = 0.5 mL/min) t_R = 41.25 min(minor), t_R = 48.31 min(major).

2f. 61% ee; ¹H NMR (300 MHz, CDCl₃) δ 3.75 (s, 3 H), 3.93 (s, 3 H), 6.37 (dd, J ₁ = 1.07 Hz, J ₂ = 1.39 Hz, PhH, 1 H), 6.81 (dd, J ₁ = 1.23 Hz, J ₂ = 1.25 Hz, PhH, 1 H), 6.97 (s, 1 H), 7.18 (m, PhH, 2 H), 7.55 (t, J = 1.95, 3.47 Hz, PhH, 2 H); EIMS (m/z, %): 397 (M⁺ + 1,22.66), 396 (M⁺, 100), 270 (27.30), 269 (82.24), 261 (59.73), 237 (19.36), 139 (18.82), 135 (46.37); FT-IR (KBr): 3005, 2968, 2940, 2838, 1764, 1609, 1568, 1492, 500 cm^-1; Anal. calcd for C₁₆H₁₃O₄I: C, 48.51; H, 3.31. Found: C,48.93; H, 3.77. HPLC (Chiral cel AD, hexane-iPrOH = 80:20, flow rate = 0.7 mL/min) t_R = 13.92 min(minor), t_R = 16.47 min(major).